Drug Profile
Research programme: plasma kallikrein inhibitors - Attune Pharmaceuticals
Alternative Names: ATN-035; ATN-XXXLatest Information Update: 04 Jan 2023
Price :
$50
*
At a glance
- Originator Attune Pharmaceuticals
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hereditary angioedema
Most Recent Events
- 04 Jan 2023 Preclinical development is ongoing in Hereditary-angioedema in USA (PO) (Attune pharmaceutic Pipeline, January 2023)
- 06 Mar 2017 Attune Pharmaceuticals plans phase I pharmacokinetic studies for Hereditary angioedema (In volunteers) in Australia (ACTRN12618000430235)
- 01 Mar 2017 Preclinical trials in Hereditary angioedema in USA (PO), before March 2017